Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.

Altimmune management will host a conference call at 8:30 am E.T. on March 15 to discuss financial results and provide a business update.

Conference Call Information:

  
Date:

Time:

Domestic Dial-in:

International Dial-in:

Conference ID:

Webcast:

Tuesday, March 15

8:30 am Eastern Time

(844) 615-6509

(918) 922-3148

4557398

https://edge.media-server.com/mmc/p/5www3cgz
  

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn

Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt

Chief Financial Officer

Phone: 240-654-1450

reisenstadt@altimmune.com



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!